NasdaqGS - Delayed Quote • USD
DBV Technologies S.A. (DBVT)
At close: April 25 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.15 | -0.21 | -0.67 | -0.81 |
| Low Estimate | -0.17 | -0.23 | -0.76 | -1.14 |
| High Estimate | -0.12 | -0.18 | -0.49 | -0.42 |
| Year Ago EPS | -0.49 | -0.11 | -1.3 | -0.67 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 6.03M | 2.25M | 12.86M | 9.35M |
| Low Estimate | 410k | 1.57M | 7.25M | 6.28M |
| High Estimate | 8.88M | 3.19M | 15.67M | 13.77M |
| Year Ago Sales | -- | 1.63M | 5.08M | 12.86M |
| Sales Growth (year/est) | -- | 38.00% | 153.20% | -27.30% |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 6/30/2023 | 9/30/2023 |
|---|---|---|---|---|
| EPS Est. | -0.18 | -0.2 | -0.2 | -0.24 |
| EPS Actual | -0.49 | -0.11 | -0.13 | -0.09 |
| Difference | -0.31 | 0.09 | 0.07 | 0.15 |
| Surprise % | -172.20% | 45.00% | 35.00% | 62.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | -0.15 | -0.21 | -0.67 | -0.81 |
| 7 Days Ago | -0.14 | -0.21 | -0.66 | -0.8 |
| 30 Days Ago | -0.15 | -0.21 | -0.67 | -0.81 |
| 60 Days Ago | -0.23 | -0.19 | -0.76 | -0.82 |
| 90 Days Ago | -0.23 | -0.18 | -0.76 | -0.82 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | DBVT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 69.40% | -- | -- | 2.60% |
| Next Qtr. | -90.90% | -- | -- | 13.40% |
| Current Year | 48.50% | -- | -- | 5.20% |
| Next Year | -20.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 21.22% | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/21/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/13/2023 |
| Maintains | Goldman Sachs: Sell to Sell | 11/2/2023 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 8/1/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/1/2023 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 5/11/2023 |
Related Tickers
XCUR Exicure, Inc.
0.5090
-1.17%
IVA Inventiva S.A.
3.1600
-2.77%
CMRA Comera Life Sciences Holdings, Inc.
0.0361
-11.95%
NBSE NeuBase Therapeutics, Inc.
0.4420
+4.99%
MOLN Molecular Partners AG
3.8900
+7.76%
LIPO Lipella Pharmaceuticals Inc.
0.7085
-0.60%
LIXT Lixte Biotechnology Holdings, Inc.
3.2200
-1.83%
SNTI Senti Biosciences, Inc.
0.2787
-0.78%
ALVR AlloVir, Inc.
0.8000
+2.56%
CMMB Chemomab Therapeutics Ltd.
0.6590
-1.64%